What is the dividend for Eli Lilly in 2024?
The LLY stock shareholders received the last dividend payment of $1.30 per share on March 8, 2024 .
8, 2023 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has announced a 15% increase in its quarterly dividend and declared a dividend for the first quarter of 2024 of $1.30 per share on outstanding common stock.
Eli Lilly and Co's Dividends per Share for the three months ended in Dec. 2023 was $1.13. During the past 12 months, Eli Lilly and Co's average Dividends Per Share Growth Rate was 15.30% per year. During the past 3 years, the average Dividends Per Share Growth Rate was 15.20% per year.
Eli Lilly and Company (NYSE:LLY) has announced that it will be increasing its dividend from last year's comparable payment on the 8th of March to $1.30. This takes the annual payment to 0.8% of the current stock price, which unfortunately is below what the industry is paying.
Eli Lilly stock (symbol: LLY) underwent a total of 4 stock splits. The most recent stock split occured on October 16th, 1997.
- Broadcom (AVGO) Source: Sasima / Shutterstock.com. Broadcom (NASDAQ:AVGO) is the most expensive stock on this list on a per-share basis. ...
- Deckers Outdoor (DECK) Source: BalkansCat / Shutterstock. ...
- Nvidia (NVDA) Source: Poetra.RH / Shutterstock.com.
LLY Stock 12 Months Forecast
Based on 18 Wall Street analysts offering 12 month price targets for Eli Lilly & Co in the last 3 months. The average price target is $846.43 with a high forecast of $1,000.00 and a low forecast of $650.00. The average price target represents a 9.84% change from the last price of $770.61.
Overall, Eli Lilly is on a path to deliver very strong sales growth in the coming years. The obesity drugs market in particular is expected to rise a whopping 16 times to over $100 billion by 2030, and it will largely be dominated by Eli Lilly and Novo Nordisk.
On average, Wall Street analysts forecast that Lilly will grow its earnings at nearly 30% annually over the next five years. BofA analysts think the company might do even better than that.
Summary. Eli Lilly's stock is overvalued by around 27% despite its success in developing drugs for diabetes and obesity. LLY has strong financial performance with steady revenue growth and profitability expansion.
Who owns the most stock in Eli Lilly?
| Holder | # of Shares | Type |
|---|---|---|
| Lilly Endowment Inc | 98,898,810.00 | Insider |
| Vanguard | 63,468,959.00 | Institution |
| Vanguard Index Funds | 58,783,991.00 | Institution |
| iShares | 30,959,341.00 | Institution |
Key Points. Weight control drugs like Mounjaro and Zepbound drove 28% sales growth for Lilly last quarter. Bank of America says Lilly has other drugs in its pipeline that could grow Lilly even more. Be that as it may, weight loss drugs are the main reason Eli Lilly stock is so greatly outperforming its Big Pharma peers ...
Eli Lilly and Company ( LLY ) pays dividends on a quarterly basis. Eli Lilly and Company ( LLY ) has increased its dividends for 10 consecutive years.
Eli Lilly Stock Forecast 2026-2030
These five years would bring an increase: Eli Lilly price would move from $1,217 to $2,040, which is up 68%. Eli Lilly will start 2026 at $1,217, then soar to $1,235 within the first six months of the year and finish 2026 at $1,419. That means +88% from today.
LLY's 12-month-forward PE to Growth (PEG) ratio of 1.74 is considered a poor value as the market is overvaluing LLY in relation to the company's projected earnings growth due. LLY's PEG comes from its forward price to earnings ratio being divided by its growth rate.
Eli Lilly and Company's LLY stock declined 2.3% on Friday after it announced that an FDA decision on its regulatory filing for an important pipeline candidate, donanemab, its anti-amyloid beta antibody for early symptomatic Alzheimer's disease, will be delayed.
For now at least, analysts are anticipating S&P 500 earnings growth will continue to accelerate in the first half of 2024. Analysts project S&P 500 earnings will grow 3.9% year-over-year in the first quarter and another 9% in the second quarter.
Based on Nvidia's split history and its current price, a 2024 split is likely. Analyst Ken Mahoney, president and CEO of Mahoney Asset Management, agrees, although with a slightly longer timeline. Mahoney recently told Bloomberg News that he predicts Nvidia will split within 12 months.
The S&P 500 generated an impressive 26.29% total return in 2023, rebounding from an 18.11% setback in 2022. Heading into 2024, investors are optimistic the same macroeconomic tailwinds that fueled the stock market's 2023 rally will propel the S&P 500 to new all-time highs in 2024.
Future Growth
Eli Lilly is forecast to grow earnings and revenue by 27.2% and 15.9% per annum respectively. EPS is expected to grow by 27.1% per annum. Return on equity is forecast to be 64.8% in 3 years.
How much market cap did Eli Lilly lose?
Pharmaceutical company Eli Lilly (LLY) dipped 4.37 per cent Friday to US $352.30 — erasing over US $15 billion in market cap — after a Twitter Blue verified account impersonating the brand promised free insulin.
Another stock and that is starting to look expensive is pharmaceutical company Eli Lilly. Up 30% on the year and up 143% over the last 12 months, LLY stock is currently trading at an all-time high of $770 per share.
| High | $1,000.00 |
|---|---|
| Median | $820.36 |
| Low | $540.00 |
| Average | $806.68 |
| Current Price | $773.14 |
Lilly Again Earns a Spot on Fortune Magazine's list of 50 Best Companies in America for Minorities "It's an honor to continue to be named to Fortune's prestigious list," said Candice P. Lange, Lilly's director of work force partnering. "The recognition reflects the energy and hard work of many people.
The New Jersey facility has been under scrutiny by the U.S. Food and Drug Administration since 2019 when inspectors found quality control data had been deleted and not appropriately audited, Reuters has reported. The plant has also produced several cancer medications and a COVID-19 therapy.
